Action Of Glp-1 In Skeletal Muscle

This review critically examines current data on the effects of GLP-1 RAs on body composition, explores the underlying pathophysiological mechanisms of skeletal muscle wasting, and offers evidence-based strategies for attenuating these potential adverse outcomes.

Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) improve glycaemia and reduce body weight, yet their organ-level actions on skeletal muscle remain incompletely defined.

New research reveals how GLP-1 muscle loss may accelerate cellular agingand what experts recommend to protect long-term health.

Recent studies have shown that pharmacologic weight loss with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and combination therapies is approaching magnitudes achieved with surgery. However, as more weight loss is achieved, there is concern for potential adverse effects on muscle quantity, composition, and function.

GLP-1 receptor agonists are transforming obesity and diabetes care, but may reduce skeletal muscle mass, raising concerns about sarcopenic obesity.

As GLP-1(7-36)amide exerts a glycogenic effect in the rat skeletal muscle, the present data suggest that the action of the peptide in the muscle glucose metabolism may be increased in states of insulin deficiency accompanied or not by insulin resistance.